Squamous cell lung cancer (SQCC) is the second most frequent lung cancer. Treatment for this malignancy is determined by stage, although this system lacks precision at an individual patient level with respect to predicting likelihood of recurrence and death from cancer. Tumor phenotype has been shown to be driven by the underlying gene expression. The present study aims to identify a gene expression signature capturing the altered key pathways in cancer biology for SQCC patients. We have identified a 12-gene signature prognostic for SQCC that is independent of stage. Importantly its prognostic independence has been consistently validated either in silico or by qPCR in multiple independent SQCC cohorts. This signature enables us to identify low and high risk patients with distinct survival outcomes that potentially may direct post-operative therapy. The signature has the potential to play an important role in refining lung cancer management. Experimental Design: A published microarray dataset from 129 SQCC patients was used as a training set to identify the minimal gene set prognostic signature. This was selected using the MAximizing R Square Algorithm (MARSA), a novel heuristic signature optimization procedure based on goodness-of-fit (R square). The signature was tested internally by leave-one-out-crossvalidation (LOOCV), and then externally in 3 independent public lung cancer microarray datasets: 2 datasets of NSCLC and one of adenocarcinoma (ADC) only. Quantitative-PCR (qPCR) was used to validate the signature in a fourth independent SQCC cohort.
Introduction
Identifying gene expression signatures that capture altered key pathways/regulators in carcinogenesis may discover molecular subclasses and predict patient outcomes (1) . Several prognostic gene expression signatures have been published for non-small cell lung cancer (NSCLC) (2) (3) (4) (5) (6) (7) (8) and its adenocarcinoma (ADC) subtype (9) (10) (11) (12) . Fewer studies have been performed to identify prognostic signatures specific for lung squamous cell carcinoma (SQCC) (13, 14) , but their validation in independent cohorts or datasets has been limited.
Factors such as patient/sample heterogeneity, small sample size, variation in microarray platforms, RNA preparation and hybridization protocols could all contribute to difficulties in validation of gene expression signatures. In addition, the loss of information through arbitrary exclusion of patients or genes prior to analysis may play an important role. Supervised data mining methodology assigns cases into good and poor prognosis subgroups at specified time points (13, 15) . This arbitrary assignment of a cutoff to split good/poor prognosis cases could be problematic due to the non-linear relationships between gene expression and patient survival.
Other investigators have compared two extremes in outcome (very early death versus long survival) (3, 12) ; however, this approach may result in significant information loss, for almost half of the cases with intermediate survival are excluded from analysis, thereby leading to high finite sample variation (16) , and making the cohort under study less representative. This variability explains, therefore, why the validation of the identified signature published to date has been challenging.
It is estimated that most tissues express only 30-40% of genes (17) or 10,000 to 15,000 genes (18) . Furthermore, among the expressed genes from similar tissue types, only a small fraction is differentially expressed. Only these differentially expressed genes distinguish one In addition, signatures are generated using a forced forward inclusion procedure pre-determined by the rank of significance of the gene (8, 9) or the bootstrap score (13) , regardless of whether the included gene contributes to the classification ability of the signature. The lack of heuristic measures in these methods potentially reduces the robustness of these signatures.
We have applied a new heuristic MAximizing R Square Analysis (MARSA) algorithm to identify a novel 12-gene prognostic signature from a microarray dataset of 129 SQCC patient samples (13) . To show the robustness of this signature, we tested it in multiple independent cohorts of histology-defined patients with microarray or quantitative-RT-PCR (qPCR). ADC) from Sungkyunkwan University (SKKU) without pre-operative therapy (7), and 327 ADC samples from the NCI Director's Challenge Consortium for the Molecular Classification of ADC (DCC) (11) . UM was used as the training set, while the remaining three datasets served as independent test sets. In addition, qPCR validation of the signature was carried out in 62 SQCC Table   1S ). The signature was then verified by an internal validation by the leave-one-out-crossvalidation (LOOCV).
MATERIALS AND METHODS

Datasets
Validation of the expression signature:
The signature generated from the training set and verified by LOOCV was then validated in silico in 3 independent datasets from Duke (3), SKKU (7), and DCC (11) and then by qPCR in our own UHN cohort. The independent prognostic value of the signature was tested in the multivariate Cox proportional hazard model, and adjusted for stage, age and sex. Statistical analyses were performed using SAS v9.1 (SAS Institute, CA).
Quantitative RT-PCR (qPCR): qPCR was performed on the ABI 7900HT real-time PCR system (AppliedbioSystems, Foster city, CA). Primers were designed primarily within the target sequences of the selected probe-sets; however, if no primer could be found in this area, primers were designed in the CDS of the target gene (Supplemental Table 2S ). PCR reaction optimization has been described previously (21) . Five ng of cDNA was used for each reaction, with overall survival at p<0.005. The exclusion selection procedure started with these 96ps and by stepwise exclusion, probe set 211514_at was identified as its last one. This was followed by the inclusion procedure using 211514_at as its starting probe-set. The procedure included one probe-set at a time until all 96ps were included. The exclusion procedure identified the largest R 2 of 0.77 with a combination of 12ps (12-gene) ( Figure 1B ). PCA analysis and the multivariate Cox proportional hazard model with stepwise selection revealed that 4 PCs were significantly associated with survival at p<0.05 (Supplemental Table 1S ). Subsequent LOOCV identified a predicting error of the signature of only 4.7% (6 cases). Thus, the 12-gene combination was established as the prognostic gene signature (Table 3) .
When the risk score was dichotomized at the optimal cutoff (-0.056, Supplemental Table   1S ), the 12-gene signature classified 63 and 66 SQCC patients into low-and high-risk groups, respectively with a significant difference in overall survival (HR=11.47, 95%CI 4.78-27.49, p<0.0001, Figure 1C ). No significant association of the 12-gene signature with T and N stages, age and sex was noted (data not shown). Multivariate analysis revealed that the signature was an independent prognostic factor after adjusted for stage, age and sex (HR=15.18, 95% CI 6.04-38.11, p<0.0001, Supplemental Table 4S ).
In silico validation of the new 12-gene signature
We were excluded from further analysis ( Figure 2B ) and II SQCC (HR=7.69, 95% CI 0.87-67.67, p=0.066, Figure 2C ). The high risk group was associated with older patients (age ≥65 years, p=0.02) but not with stage or sex (data not shown). Furthermore, multivariate analysis showed that the signature was an independent prognostic factor in SQCC (HR=3.05, 95%CI 1.14-8.21, p=0.027) but not in ADC (HR=1.73, 95% CI 0.59-5.12, p=0.322, Table 2 and Supplemental Table 5S ) after adjustment for stage, age and sex.
The SKKU dataset (7) included 138 stage I-III NSCLC (76 SQCC and 62 ADC) patients profiled using the U133 plus 2 chip. This is the only NSCLC microarray dataset from Asia.
Validation of our signature used recurrence-free survival as this is the only endpoint reported for this study. Because the GEO database has no raw data, we downloaded the expression data which was already GCRMA-preprocessed and log2-transformed. Gene expression level was Zscore transformed and risk score was derived using the formula listed in Supplemental Table 1S . Figure   2E ) and stage II and III (HR=6.20, 95% CI 1.84-20.86, p=0.003, Figure 2F ). The risk groups
were not significantly associated with stage, sex and age (data not shown). Multivariate analysis Table 2 and Supplemental   Table 5S ) after adjustment for stage, age and sex.
To determine further whether the signature was prognostic in ADC, the 12-gene signature was tested in the largest available ADC microarray dataset from the NIH Director's Challenge Consortium study (11) , which included 442 samples. Among them, 327 patients did not receive any adjuvant chemotherapy or radiotherapy and had follow-up longer than 1 month. The 12-gene signature was not prognostic (HR=1.26, 95%CI 0.87-1.81, p=0.221, Supplemental Figure 1C ).
Multivariate analysis showed that it was not an independent prognostic factor in ADC (HR=1.23, 95% CI 0.85-1.78, p=0.267, Table 2 ). These data confirm that the signature was not prognostic in ADC.
qPCR validation in UHN SQCC cohort
qPCR validation of the 12-gene signature was performed in an independent set of 62 snap-frozen SQCC samples from UHN without pre-or post-operative therapy. Fold change was calculated using 2 -∆∆Ct method and then Z-score transformed. Risk score was generated using parameters listed in Supplemental Table 1S . When risk score was dichotomized at -0.056, the 12-gene signature was able to separate 41 and 21 SQCC into low and high risk group with significant difference in 5-year overall survival (HR=4.00, 95%CI 1.20-13.31, p=0.024, Figure   2G ). Stratified analysis by stage revealed that the signature was able to separate low-and highrisk groups with different survival outcomes; however, the significance was marginal due to the small sample size (Stage I: HR=3.39, 95%CI 0.66-17.47, p=0.145, Figure 2H and stage II&III:
HR=5.33, 95%CI 0.88-32.19, p=0.069, Figure 2I ). The risk groups were not associated with The composition of the 12-gene signature Table 3 shows the members of the12-gene signature and their ranks of expression level, variance, and significance in the Veridex dataset (in decreasing order of importance). Notably, the expression level of individual genes varies greatly, from very high levels as for RPL22 (rank in the top 0.6%) to extremely low levels for PTPN20A/B (ranked at 99.7%). The standard deviation value also varies greatly, from very large as for G0S2 (rank at 1.9% of the total) to very small for RIPK5 (rank at 97.5% of the total). These data showed that the low-expression and low-variabity genes were as important as those with higher expression and higher variability.
Gene ontology (GO) (27) and KEGG pathways (26, 28) annotations revealed the involvement of several of the prognostic genes in signal transduction (e.g., VEGFA, TNFRSF25), cell cycle (e.g., VEGFA, G0S2), apoptosis (e.g., TNFRSF25), adhesion (e.g., Table   6S ).
Protein-protein interaction network analysis
To assess the potential SQCC-specific biological relevance of the 12-gene signature genes further, we evaluated the functional relationship between our 12-gene signature and the reported Raponi (13) and Sun (8) table 6S , 7S, and 8S).
DISCUSSION
We describe here the MAximizing R Square Algorithm (MARSA), a heuristic signature selection method that includes only genes contributing to the separation ability of the signature. Table 2 ) but not in the corresponding ADC datasets (Table 2) .Further, we confirmed the absence of the prognostic value of the 12-gene signature in the largest available ADC dataset from DCC containing 442 ADC samples (Table 2) . Importantly, qPCR validation in another independent cohort confirmed that the signature was an independent prognostic factor in SQCC (Table 2) . Combined, our data strongly suggested that the 12-gene signature is a valuable prognostic factor for SQCC.
A prognostic factor provides information about a patient's overall outcome, that is independent of therapy, while a predictive biomarker gives information about the effect of a therapeutic intervention. When establishing a prognostic factor, it is best to evaluate outcome in patients who have not received systemic adjuvant therapy after surgery since chemotherapy has been shown to change the course of the disease, and to improve overall survival significantly. In the present study, samples in the UM dataset were collected from patients between October 1991
and July 2002 who were not likely to have receive adjuvant chemotherapy. Importantly, the signature was computationally confirmed in the two validation datasets (Duke and SKKU), which were used to explore prognostic signatures, and validated by qPCR in 62 patients in the UHN cohort of patients who had not received adjuvant therapy. Therefore, in these untreated patients our 12-gene signature is prognostic, and not predictive.
The cellular origin and pathogenesis of SQCC and ADC remain controversial. In contrast to ADC, SQCC tends to arise in the epithelium of large airways and its etiology is clearly linked to smoking, suggesting different pathogenetic differences between the two lung cancer types 
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Copyright © 2010 American Association for Cancer Research (29) . This is supported by differences in the occurrence of key genetic alterations in the two types of cancer (30) . While frequently mutated in ADC, KRAS (31, 32) and EGFR (33) mutations occur very infrequently in SQCC. In contrast, P53 mutation ( 
